ABSTRACT: Bronchopulmonary dysplasia (BPD) is characterized by arrested alveolar development and complicated by pulmonary hypertension (PH). NO promotes alveolar growth. Inhaled NO (iNO) ameliorates the BPD phenotype in experimental models and in some premature infants. Arginosuccinate synthetase (ASS) and arginosuccinate lyase (ASL) convert L-citrulline to L-arginine; L-citrulline is regenerated during NO synthesis from L-arginine. Plasma levels of these NO precursors are low in PH. We hypothesized that L-citrulline prevents experimental O 2 -induced BPD in newborn rats. Rat pups were assigned from birth through postnatal day (P) 14 to room air (RA), RA ϩ L-citrulline, 95% hyperoxia (BPD model), and 95%O 2 ϩ L-citrulline. Rat pups exposed to hyperoxia had fewer and enlarged air spaces and decreased capillary density, mimicking human BPD. This was associated with decreased plasma L-arginine and L-citrulline concentrations on P7. L-Citrulline treatment significantly increased plasma Larginine and L-citrulline concentrations and increased ASL protein expression in hyperoxia. L-Citrulline preserved alveolar and vascular growth in O 2 -exposed pups and decreased pulmonary arterial medial wall thickness (MWT) and right ventricular hypertrophy (RVH). Increased lung arginase (ARG) activity in O 2 -exposed pups was reversed by L-citrulline treatment. L-Citrulline supplementation prevents hyperoxia-induced lung injury and PH in newborn rats. L-Citrulline may represent a novel therapeutic alternative to iNO for prevention of BPD. (Pediatr Res 68: 519-525, 2010) B ronchopulmonary dysplasia (BPD), the chronic lung disease that follows acute respiratory failure after premature birth, is the most common complication in premature infants born Ͻ28 wk gestation, with an incidence of 30 -50% (1). BPD currently lacks specific treatment or prevention strategies. BPD interrupts normal lung development and results in arrested alveolar and vascular growth (2,3). The extent to which the disruption of lung growth leads to an earlier or more severe decline in respiratory function in later life is unknown (4). Case reports are emerging describing arrested alveolar growth in older children (5) and early onset emphysema in young adults (6) who were diagnosed with BPD.
B ronchopulmonary dysplasia (BPD), the chronic lung disease that follows acute respiratory failure after premature birth, is the most common complication in premature infants born Ͻ28 wk gestation, with an incidence of 30 -50% (1) . BPD currently lacks specific treatment or prevention strategies. BPD interrupts normal lung development and results in arrested alveolar and vascular growth (2, 3) . The extent to which the disruption of lung growth leads to an earlier or more severe decline in respiratory function in later life is unknown (4) . Case reports are emerging describing arrested alveolar growth in older children (5) and early onset emphysema in young adults (6) who were diagnosed with BPD.
Evidence suggests that NO promotes lung growth (7, 8) . Lungs of endothelial NOS (eNOS)-deficient mice have a paucity of distal arteries and reduced alveolarization (9) and are more susceptible to disrupted lung growth after exposure to mild hypoxia and hyperoxia (8) . Arrested alveolar growth in newborn rats after VEGF inhibition and in the chronically ventilated premature sheep and baboon models of BPD are associated with decreased lung eNOS protein and NO production. Inhaled NO (iNO) improves vascular and alveolar growth in these animal models (10 -12) . These data suggest that NO deficiency contributes to the decreased alveolarization in experimental BPD. Most recent randomized human trials suggest that iNO decreases the incidence of BPD in subsets of premature babies (13) (14) (15) . Inconsistent efficacy, complexity of iNO delivery in nonintubated patients, and high cost provide rationales for efficacious alternatives to iNO.
Endogenous NO is produced from the metabolism of Larginine to L-citrulline, two amino acids generated by the urea cycle (16) . L-Citrulline to L-arginine recycling in endothelial cells by the enzymes arginosuccinate synthetase (ASS) and arginosuccinate lyase (ASL) is proposed to be the principal mechanism for sustaining local L-arginine availability for eNOS-catalyzed NO production (17) (Fig. 1) . Polymorphisms in the gene encoding carbamoylphosphate synthetase 1, the mitochondrial enzyme catalyzing the rate-limiting step in hepatic L-citrulline formation via the urea cycle, influences NO metabolite concentrations and NO-mediated vasodilation in humans (18) . Infants with persistent pulmonary hypertension of the newborn (PPHN) or after bypass surgery for congenital heart disease have low plasma concentrations of arginine, citrulline, and NO metabolites (NOx) (19, 20) , and this can be reversed by oral citrulline supplementation (21, 22) . In addition to NO production, an adequate supply of precursor molecule is necessary to maintain the NOS complex in its "coupled" state (23) . Uncoupling of NOS results in free radical oxygen production that may potentiate vascular damage and dysfunction (23) . Thus, decreased concentrations of NO precursors and breakdown products suggest that inadequate NO production contributes to PPHN and abnormal vascular function. We hypothesized that L-citrulline supplementation preserves alveolar growth and prevents pulmonary hypertension (PH) in a model of chronic oxygen-induced BPD in newborn rats.
MATERIALS AND METHODS
All procedures and protocols were approved by the Animal Health Care Committee of the University of Alberta. Expanded methods are available in the online as supplementary material (http://links.lww.com/PDR/A63).
Animal model. Experimental BPD was induced as previously described (24, 25) . Sprague-Dawley rats (Charles River, Saint Constant, QC, Canada) were exposed to normoxia (21% O 2 ; n ϭ 90) or hyperoxia (95% O 2 , BPD model; n ϭ 90) from birth to postnatal day (P) 7, 10, or 14 in sealed Plexiglas chambers with continuous O 2 monitoring (BioSpherix, Redfield, NY; supplementary material; http://links.lww.com/PDR/A63).
Experimental protocol. Newborn rat pups were randomized to four groups: one normoxia (21%, control group; n ϭ 45), two normoxia ϩ L-citrulline (n ϭ 45), three hyperoxia (95% O 2 , BPD model; n ϭ 45), and four hyperoxia ϩ L-citrulline (n ϭ 45). L-Citrulline was administered daily from P4 to P14 via s.c. injection. The dose (8 g/m 2 /d) was based on the effective L-citrulline dosage reported in the literature (21) . Controls received normal saline vehicle. From P14 to P21, rat pups were allowed to recover in 21% oxygen. Among animals housed in hyperoxia for 14 d, 26 of the 30 untreated rats in the O 2 -induced BPD group survived; all 30 citrulline-treated rats in the O 2 -induced BPD group survived the study protocol.
Plasma amino acid levels. Amino acids (citrulline, arginine, and ornithine) were analyzed using a Hitachi 8800 (Hitachi USA) amino acid analyzer, and NOx were measured using a Sievers 280i instrument (GE Analytical Instruments, Boulder, CO) as previously described (21) O (24,25) . Lungs were paraffin embedded, cut in 4-m thick serial sections, and lung sections were stained with hematoxylin and eosin (H&E). Alveolar structures were quantified using the mean linear intercept as described (25) (supplementary material; http://links.lww.com/PDR/A63).
Barium-gelatin angiograms. Barium was instilled into the pulmonary vasculature as previously described (24, 25) (supplementary material; http://links.lww.com/PDR/A63). Barium-filled pulmonary arteries were counted per high-powered field (100ϫ magnification). Lungs of five animals/group, five sections/lung, and 10 high-power fields/section were counted.
Right ventricular hypertrophy and pulmonary artery remodeling. Right and left ventricles including the septum were weighed separately to determine the right ventricle (RV) to left ventricle (LV) ϩ septum ratio (S; RV/LVϩS) as an index of right ventricular hypertrophy (RVH) (24) . To assess pulmonary artery remodeling, the percent medial wall thickness (MWT) was calculated as (2 ϫ wall thickness/external diameter) ϫ100% (24) .
Western blot analysis. Whole rat lungs were used to determine eNOS, ASS, ASL, and arginase (ARG) II protein expression by Western blot using a modification of our previously published methods (26) (supplementary material; http://links.lww.com/PDR/A63).
ARG activity. ARG activity in frozen-lung tissue was measured by determining the amount of urea generated by the enzyme (27) 
RESULTS
Plasma concentrations of NO precursors are decreased in O 2 -induced BPD in newborn rats. L-Citrulline and L-arginine plasma levels were significantly decreased in hyperoxicexposed animals on P7 compared with room air (RA) controls ( Fig. 2A inset and B) . L-Citrulline supplementation significantly increased the plasma amino acids concentrations ( Fig.  2A-C) . Plasma NOx levels were not significantly different between untreated RA and hyperoxic-exposed animals. LCitrulline supplementation significantly increased P7 plasma NOx levels in both normoxia-and hyperoxia-exposed rat pups (Fig. 2D) .
L-Citrulline prevents alveolar simplification in O 2 -induced BPD in newborn rats. Hyperoxic-exposed rat pups displayed the characteristic features of alveolar simplification, with larger and fewer alveoli and decreased septation compared with normoxic animals (Fig. 3A) . L-Citrulline preserved alveolar growth in hyperoxic rats as quantified by the mean linear intercept and septal counts (Fig. 3B ) measured on P21. No effect of L-citrulline was observed in control rats.
L-Citrulline preserves lung vascular growth in O 2 -induced BPD in newborn rats. Hyperoxic-exposed rat pups showed a significant decrease in pulmonary arterial density compared with normoxic rat pups as demonstrated by barium angiograms performed on P21 (Fig. 4) . Hyperoxia-exposed rat pups treated with L-citrulline exhibited increased arterial density when compared with untreated hyperoxic rat pups (Fig. 4) . L-Citrulline had no effect on normoxic rats.
L-Citrulline prevents PH in O 2 -induced BPD in newborn rats. Chronic exposure to hyperoxia for 14 d was associated with a significant increase in RVH (Fig. 5A) and %MWT of small pulmonary arteries measured on P21 (Fig. 5B) . LCitrulline attenuated these structural features of PH as indicated by a reduction in RV/LV ϩ S and %MWT ( Fig.  5A and B) .
Hyperoxia alters the expression of proteins involved in the citrulline-arginine-NO cycle in a postnatal age-dependent manner. eNOS expression was not statistically different between control and hyperoxic rat lungs on P7 or P14 but was transiently increased on P10 in lungs from hyperoxia-exposed rats. There was a significant increase in protein abundance of ASL throughout the 14 d exposure to hyperoxia; ASS protein expression was also significantly increased in hypoxic rat lungs on P7 and P10 but not on P14 (Fig. 6A and B) .
L-Citrulline increases protein expression of ASL in hyperoxia-exposed rat lungs. L-Citrulline treatment did not alter eNOS or ASS lung protein abundances in normoxia-or hyperoxia-exposed rat lungs on P7 or P10 (Fig. 7) . However, under hyperoxic conditions, L-citrulline increased ASL protein expression at both time points. Unexpectedly, L-citrulline treatment induced ARG II expression in normoxic and hyperoxic lungs on P7 and P10 (Fig. 7A-D) .
Hyperoxia and L-citrulline treatment synergistically increase ARG II protein expression in newborn rat lungs. Chronic exposure to hyperoxia caused a significant increase in pulmonary ARG II expression (Fig. 8A and B) ; the elevated ARG II protein abundance in hyperoxic lungs was further increased by L-citrulline therapy (Fig. 8A and B) .
Chronic exposure to hyperoxia was associated with a significant increase in lung ARG activity on P7 (Fig. 8C) . L-Citrulline administration normalized lung ARG activity.
DISCUSSION
We demonstrate that L-citrulline preserves alveolar and lung vascular development and prevents PH in an experimental O 2 -induced BPD model in newborn rats. Our results suggest a pivotal role for the L-citrulline-NO pathway in the developing lung. This pathway may be an effective target to protect the lung from impaired alveolar development.
The availability of intracellular arginine is potentially a rate-limiting factor in the production of endogenous NO. Oral supplementation with L-arginine has been used in a variety of clinical conditions to improve NO-mediated vascular function (28) . Experimental and human studies suggest that after oral administration, L-arginine is extensively metabolized by ARG in the gut wall and liver (29, 30) . This may limit its bioavailability as a substrate for NOS and subsequent effects on vascular function. In addition, supplemental L-arginine enhances ARG expression and activity, thus reducing the effectiveness of L-arginine therapy. In contrast, L-citrulline is not metabolized in the intestine or liver and does not induce tissue ARG I, but rather inhibits its activity and is more effective in maintaining plasma L-arginine concentrations than L-arginine itself in healthy volunteers (31) . The physical relationship of the enzymes in cycling citrulline and arginine and producing NO (ASS, ASL, and eNOS) may also make L-citrulline a more effective extracellular supplement to improve NO production (32) (33) (34) (35) .
L-citrulline has no recognized toxicity and is used clinically as replacement therapy for children with certain types of urea cycle defects (36) . Furthermore, oral L-citrulline, as a precursor to L-arginine and NO, improves sickle cell disease symptoms in children (37) and decreases PH after surgery for congenital heart disease (21, 22) .
Our data suggest that plasma L-citrulline and L-arginine concentrations can be markedly increased by supplemental L-citrulline (Fig. 2) . This limitation in metabolic precursors C. L-Citrulline decreases pulmonary ARG activity in O 2 -induced BPD in newborn rats. Hyperoxic-exposed rats had significantly increased lung ARG activity on P7. L-Citrulline normalized lung ARG activity in hyperoxic-exposed rats. ARG activity was unchanged in L-citrulline-treated control rats. n ϭ 5/group, *p Ͻ 0.05. could contribute to low NO production and, thus, to arrested alveolar growth and PH in the O 2 -induced BPD model. Our data parallel findings in human infants with PPHN and in infants and children with PH after congenital heart disease surgery (19, 20) . Our data also suggest that L-citrulline increases expression of ASL in the O 2 -injured lungs (Fig. 7) . L-Citrulline exhibits good bioavailability with ease of movement across cellular membranes. The cytosolic portion of the urea cycle that includes ASS and ASL enables localized, intracellular production of L-arginine from citrulline within the pulmonary endothelium. This recycling pathway might be important in sustaining the production of NO in endothelial cells, especially when availability of L-arginine for NO synthesis becomes limiting. Although total eNOS protein expression did not change with citrulline treatment, the data suggest that eNOS function was enhanced. This is supported by the finding of increased NOx on d 7 in normoxic and hyperoxic rats (Fig. 2D) , which is a reflection of increased NOS activity and NO production. Although plasma levels of NOx were only transiently increased by L-citrulline treatment, local pulmonary production of NO may be inferred from the improved lung architecture and attenuated PH. L-citrulline's efficacy in this study mirrored those obtained with iNO in experimental BPD models (10 -12) .
PH contributes to morbidity and mortality in human BPD (38) . The hyperoxic BPD model in rats also exhibits PH characterized by RVH and pulmonary artery medial wall thickening. L-citrulline attenuated RVH and pulmonary artery remodeling in this model (Figs. 4 and 5) . These findings are consistent with a recent study of L-citrulline administration in a neonatal piglet model of chronic hypoxia-induced PH (39) .
Among other mechanisms, increased ARG activity may account for abnormal airway and vascular remodeling in the hyperoxia model of BPD in newborn rats. ARGs mediate the conversion of L-arginine to urea and ornithine (40) (Fig. 1) and compete with NOS for L-arginine as substrate. Increased ARG activity in PH and other lung diseases, including asthma and cystic fibrosis, is believed to result in decreased availability of L-arginine for constitutive NOSs and consequently diminished NO production (41) (42) (43) . Interestingly, lung ARG expression and activity in the rat is developmentally regulated and expressed at the highest levels in the fetus and newborn (44) , suggesting that ARG contributes to the maintenance of high pulmonary vascular resistance during fetal life. Hyperoxia up-regulates ARG expression in the adult rat lung (45) . Herein, we show that both ARG II expression and ARG activity are increased in chronic O 2 -exposed neonatal rat lungs (Figs. 7 and 8 ). This may limit arginine availability to NOS and contribute to decreased NO production in this model (46) . Unexpectedly, we found that L-citrulline increased expression of ARG II, the isoform expressed in nonhepatic tissue (Figs. 7 and 8). It had been previously reported that L-citrulline, unlike L-arginine, does not induce tissue ARG (31) . Notably, and despite the increase in protein expression, L-citrulline normalized lung ARG activity in neonatal oxygen-induced lung injury (Fig. 8 ). An interesting link between increased ARG activity and BPD has been proposed recently. Ornithine, the downstream product of ARG activity, is further metabolized into polyamines that are involved in tissue repair and growth, and proline, the precursor for collagen formation (40) (Fig. 1) . In bleomycin-induced lung fibrosis, ARG expression and activity are also increased (47, 48) , suggesting that these enzymes contribute to lung remodeling and, thus, represent a therapeutic target.
In conclusion, this is the first report on the potential therapeutic benefit of L-citrulline in preventing O 2 -induced alveolar damage and altered angiogenesis in the developing lung. The bioavailability, safety, and efficacy of L-citrulline, combined with its low cost and ease of administration, make it an attractive therapeutic option that warrants further studies.
